California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on October 24, 2025

October 24, 2025

TEMPLAR SHIELD AND WRANGU ANNOUNCE STRATEGIC ALLIANCE TO SUPPORT SERVICENOW CUSTOMERS ACROSS NORTH AMERICA AND EMEA

EIN Presswire

October 24, 2025

Beachside Teen Treatment Center Highlights Developments in Rehab Centers in Malibu CA

EIN Presswire

October 24, 2025

Hillcrest Addresses Advancements in Adolescent Residential Treatment Centers in California

EIN Presswire

October 24, 2025

Pennant Announces Third Quarter 2025 Earnings Release and Call

GlobeNewswire

October 24, 2025

Enzon and Viskase Announce Amendment to Merger Agreement

GlobeNewswire

October 24, 2025

60 Iconic Canadian Landmarks to Light Up Blue for World Occupational Therapy Day

GlobeNewswire

October 24, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

October 24, 2025

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

GlobeNewswire

October 24, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire

$Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia$

October 24, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

GlobeNewswire

October 24, 2025

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

GlobeNewswire

October 24, 2025

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire

October 24, 2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GlobeNewswire

October 24, 2025

Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System

GlobeNewswire

October 24, 2025

Global Dental Imaging Market to Reach USD 4.69 Billion by 2030 | MarketsandMarkets™

GlobeNewswire

October 24, 2025

AI in Biotechnology Market to Reach $11.4 Billion by 2030

GlobeNewswire

October 24, 2025

Incubator Stock Review Initiates Coverage on Vystar

GlobeNewswire

October 24, 2025

Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

GlobeNewswire

October 24, 2025

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire

October 24, 2025

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

GlobeNewswire